Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy by Melero Polo, Jorge et al.
Address for correspondence: Dr. Jorge Melero Polo, Cardiology Department, Hospital Clínico Lozano Blesa de Zaragoza, 
calle San Juan Bosco 15, CP: 50009 Zaragoza, Spain, tel: +34 661 05 85 66, e-mail: jorgemeleropolo@gmail.com
Received: 2.02.2021 Accepted: 12.07.2021 Early publication date: 2.08.2021
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Echocardiographic markers of cardiac  
amyloidosis in patients with heart failure  
and left ventricular hypertrophy
Jorge Melero Polo1 , Ana Roteta Unceta Barrenechea2, Pablo Revilla Martí1,  
Raquel Pérez Palacios3, Anyuli Gracia Gutierrez4, Esperanza Bueno Juana4,  
Alejandro Andrés Gracia2, Saida Atienza Ayala5, Miguel Ángel Aibar Arregui4
1Cardiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain 
2Nuclear Medicine Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain 
3Biochemistry and Molecular Biology, IIS-Aragón, Zaragoza, Spain 
4Internal Medicine Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain 
5Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Abstract
Background: Cardiac amyloidosis (CA), following a non-invasive diagnosis, constitutes an increas-
ingly prevalent heart failure (HF) etiology. This study aims to determine which echocardiography  
findings help to diagnose CA in patients with left ventricular hypertrophy (LVH) admitted for decom-
pensated HF.
Methods: The present study is a retrospective observational study on a cohort of 85 LVH patients ad-
mitted for HF decompensation, in which 99mTc-DPD scanning was performed to rule out transthyretin 
CA. The echocardiographic findings obtained were compared between CA and non-CA groups.
Results: From a total number of 85 patients, 49 (57.6%) met the CA criteria and 36 (42.3%) were 
ruled out for the disease. Interventricular septum thickness (16 ± 3 mm vs. 14 ± 3 mm), left ventricular 
posterior wall thickness (14 ± 3 mm vs. 11 ± 2 mm), left ventricular mass (259 ± 76 g vs. 224 ± 53 g),  
left ventricular end-diastolic diameter (48 ± 7 mm vs. 53 ± 6 mm), left ventricular end-diastolic in-
dexed volume (51 ± 18 cm3/m2 vs. 59 ± 16 cm3/m2), tricuspid annular plane systolic excursion (16 ±  
± 5 mm vs. 20 ± 4 mm), right atrial area (27.4 ± 8.4 cm2 vs. 22.2 ± 5.7 cm2) and strain relative api-
cal sparing (2.2 ± 0.9 vs. 1.03 ± 0.4; p = 0.04) were significantly associated with the diagnosis of CA.
Conclusions: In patients with LVH admitted for HF decompensation, there are several echocardio-
graphic features (LVH, reduced left ventricular cavity size, strain relative apical sparing, right atrial 
dilation, and altered right ventricular function) that are associated with the diagnosis of cardiac amy-
loidosis. (Cardiol J)
Key words: cardiac amyloidosis, echocardiography, heart failure, left ventricular  
hypertrophy
Introduction
Cardiac amyloidosis (CA) is an infiltrative 
disease caused by the extracellular deposition of 
defective proteins. To date, more than 30 poten-
tially amyloidogenic proteins have been described, 
although the majority of amyloidosis with cardiac 
presentation that are present in the clinical practice 
are systemic immunoglobulin light chain (AL) and 
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is divided into the hereditary or variant (ATTR-v) 
and the senile or wild-type (ATTR-wt) forms.
Cardiac amyloidosis diagnosis required, until 
recent years, proof of amyloid material recovered 
by biopsy. Recently, a cardiac ATTR non--invasive 
diagnostic by gammagraphy with specific radiotrac-
ers and exclusion of the monoclonal component has 
been validated [1], and since, more cases, mainly 
from the wild type subtype, have been diagnosed 
without the need for histology. In fact, employing 
this approach, in recent reviews and scientific 
statements recommended histology just in two 
scenarios: a grade 1 uptake of myocardial radio-
tracer on cardiac gammagraphy or the presence 
of a monoclonal protein [2, 3].
The echocardiogram is often the first test that 
allows suspicion to the diagnosis of CA. Among 
all the characteristic echocardiographic findings 
of CA, the most frequent is left ventricular (LV) 
thickening [4]. This finding is a good starting 
point for establishing the suspicion of CA, but it 
is a non-specific finding that can be objectified by 
a multitude of causes: arterial hypertension, aortic 
valve disease, some myocardial disease or simply 
due to intensive training [5]. For all these reasons, 
some studies have sought new echocardiographic 
parameters in order to distinguish patients with 
amyloidosis from others with LV thickening of 
a different origin, especially arterial hyperten-
sion and hypertrophic cardiomyopathy [6–9]. To 
date however, none of the published studies have 
compared the echocardiographic characteristics 
of patients hospitalized for heart failure (HF) with 
final diagnosis of CA versus those with LV thicken-
ing of another cause.
Some research groups have found an ATTR 
prevalence of up to 13% in patients > 60 years old 
admitted for HF with preserved ejection fraction 
and left ventricular hypertrophy (LVH) [4]. Thus, it 
would be extremely useful to identify which echo-
cardiographic parameters allow us to increase the 
diagnostic probability of CA in this subgroup, and 
hence select the patients that could benefit from 
a cardiac gammagraphy.
The aim of the study was to compare the echo-
cardiographic findings from patients hospitalized 




The study population consisted of a consecu-
tive series of patients hospitalized in the document-
ed center between November 2013 and December 
2019, due to de novo or chronic uncompensated 
HF, who presented LVH and who subsequently 
underwent a gammagraphy with 99mTc-DPD to rule 
out CA by transthyretin. The study cases selected 
were those patients who finally met the diagnostic 
criteria of CA, and for controls by those who did 
not meet the criteria; controls were paired by sex 
and age to avoid bias against study cases (Fig. 1).
Inclusion criteria: Patients > 18 years of 
age, with an established diagnosis of HF [8] and 
LVH by echocardiogram, who underwent a DPD 
gammagraphy during a de novo HF admission or 
known HF decompensation.
Exclusion criteria: Failure to meet any of 
the inclusion criteria. Refusal to participate in the 
study.
Sample size
Given that the number of cases with a CA di-
agnosis in the selected environment was limited, 
and with the purpose of increasing the statistical 
power of the study, all patients who met the inclu-
sion criteria were selected through a sampling of 
consecutive cases.
Diagnostic criteria
For the diagnosis of transthyretin cardiac amy-
loidosis, we relied on the criteria as defined by the 
study of Gillmore et al. [1]: a grade 2–3 uptake of 
the myocardial radiotracer on cardiac gammagraphy 
with 99mTc-DPD presents a sensitivity of 91% and 
a specificity of 87% for the diagnosis of ATTR; 
this specificity increases to 100% (with respect to 
an invasive diagnosis by endomyocardial biopsy) 
by adding the criteria of absence of monoclonal 
protein in blood and urine. In the present study, 
since immunofixation was not performed in every 
patient during their hospitalization, the diagnosis 
of ATTR with grade 2–3 of gammagraphic capture 
in addition to a negative immunofixation or absence 
of diagnosis of monoclonal gammopathy in the 
monitoring was used. Considering this, although 
we can strongly state that the vast majority of the 
cardiac amyloidoses corresponded to the TTR 
subtype, it cannot be ruled out that some cases 
may correspond to other subtypes, therefore we 
did not distinguish between the different subtypes 
of amyloidosis and refer to this group as the group 
with CA. The study patients with a grade 1 uptake 
of the myocardial radiotracer or patients with 
monoclonal protein were excluded. 
Left ventricular hypertrophy was defined as 
a thickness greater than or equal to 12 mm in any 
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segment of the LV wall as measured by echocar-
diogram.
For the diagnosis of HF, the diagnostic criteria 
described in the latest European Society of Cardio-
logy (ESC) guidelines were used [10].
Clinical, analytical and echocardiographic 
collected data
For this study, the following parameters were 
collected:
 — Demographic variables: sex and age;
 — Relevant background: cardiovascular risk fac-
tors, evidences of atrial fibrillation or ischemic 
heart disease;
 — Basal New York Heart Association class;
 — Analytical parameters determined in the same 
admission in which the gammagraphy-DPD 
was requested: N-terminal pro B-type natri-
uretic peptide (NT-proBNP), ultra-sensitive 
troponin T, and glomerular filtering (CKD-EPI 
equation, expressed in mL/min/1.73 m2);
 — Echocardiographic data: echocardiograms 
were performed in cabinet echocardiograms, 
in Siemens Acuson sc2000 and Philips Envisor 
HD echocardiographs, by experienced inde-
pendent echocardiographers. The measure-
ments were obtained at the time of admission, 
without yet knowing the patient’s diagnosis, 
thus avoiding potential biases. Interventricular 
septum and LV posterior wall maximum thick-
ness, telediastolic and telesystolic LV diam-
eters, LV mass, right atrial area, right ventricle 
basal diameter and left atrial volume were 
determined in two-dimensions. The Simpson 
biplanar method was used to calculate ejec-
tion fraction. Diastolic function was evaluated 
according to the current recommendations, 
by analyzing the transmitral flow by pulsed 
Doppler and mitral annulus speed by tissue 
Doppler, evaluating both E/A and E/e’ ratio; 
pulmonary artery systolic pressure was esti-
mated through tricuspid regurgitation; right 
ventricular function was evaluated by tricuspid 
annular plane systolic excursion (TAPSE) and 
S’ measurements. The presence of pericardial 
effusion was also evaluated. During the echo-
Figure 1. The present study showed that in patients with left ventricular hypertrophy admitted for heart failure 
decompensation, several echocardiographic features are associated with the diagnosis of cardiac amyloidosis; 
TAPSE — tricuspid annular plane systolic excursion.
85 patients
Admitted because of heart failure 
decompensation with left ventricular 







associated with cardiac amyloidosis: 
• Diastolic dysfunction
• Left atrial volume
Echocardiographic characteristics not • Retrospective observational study
• The echocardiographic ndings obtained were 
 compared between cardiac amyloidosis and 
 non-cardiac amyloidosis groups
Findings associated with cardiac amyloidosis:
• Left ventricular hypertrophy degree
• Left ventricular reduced size
• Right atrial dilation
• Altered right ventricular function (TAPSE)
• Strain relative apical sparing
Suspected cardiac amyloidosis in patients with left 
ventricular hypertrophy admitted for heart failure: 
99mconsider Tc-DPD cardiac gammagraphy
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cardiogram, both heart rate and body surface 
were recorded. All measurements were per-
formed according to ESC guidelines [11];
 — Gammagraphic data: the degree of gamma-
graphic uptake was collected in the test, accord-
ing to which the diagnosis of cardiac amyloidosis 
by TTR was either confirmed or excluded. The 
degree of intensity of the radiotracer uptake 
using the Perugini scale (Fig. 2) [12].
Ethical aspects
The study was conducted in full compliance 
with current ethical standards (Declaration of Hel-
sinki); an informed consent was obtained for each 
patient’s data processing. The study was approved 
by our center’s Ethics Committee. All data were 
collected in a secure database, guaranteeing total 
confidentiality.
Statistical analysis
Statistical analysis was performed with IBM 
SPSS Statistics version 22. Variables were ex-
pressed as mean ± standard deviation. Categori-
cal variables are expressed as %. To evaluate the 
differences between these categorical variables, 
the c2 test and the Fisher test were used, as ap-
propriate in each case. For continuous variables 
with normal distribution, the Student t test was 
used for independent samples. A p-value < 0.05 
was considered statistically significant.
Results
Characteristics of the patients 
Eighty-five patients were included in the study, 
with a mean age of 80 ± 9 years and from which 75.3% 
were male. 49 (57.6%) patients met the diagnostic 
criteria for CA (ATTR group) and in 36 (42.3%) pa-
tients the disease was ruled out (non-ATTR group).
Sex distribution was similar in both groups 
(77.6% vs. 72.2%; p = 0.57). In terms of age, pa-
tients with ATTR were slightly older (83 ± 9 vs. 
77 ± 8; p = 0.003). There were no significant dif-
ferences between both groups in atrial fibrillation 
rate, heart rate or body surface (Table 1).
Patients in the control group presented 
a higher rate of cardiovascular risk factors, which 
was only statistically significant in the case of dia-
A B
C D
Figure 2. Cardiac gammagraphies with 99mTc-DPD, with different uptake grades in Perugini score; A. Grade 0; B. Grade 1; 
C. Grade 2; D. Grade 3.
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betes mellitus (56% vs. 25%; p = 0.03), although 
showing a trend in arterial hypertension (94% vs. 
71%; p = 0.105), and dyslipemia (72% vs. 53%; 
p = 0.092). Ischemic heart disease rate was also 
slightly higher in the control group (30% vs. 20%; 
p = 0.28).
Biomarkers
Troponin records on admission were sig-
nificantly higher in patients with amyloidosis than 
in controls (180 ± 272 vs. 50 ± 27; p = 0.041). 
However, no significant differences were found 
in NT-proBNP and glomerular filtration values 
between groups.
Echocardiographic parameters
Interventricular septum thickness (16 ± 3 mm 
vs. 14 ± 3 mm; p = 0.002) and LV posterior wall 
thickness (14 ± 3 mm vs. 11 ± 2 mm; p < 0.001) 
were significantly higher in the CA group. LV mass, 
both as absolute values (259 ± 76 g vs. 224 ± 53 g; 
p = 0.026) and as indexed (151 ± 43 g/m2 vs. 
123 ± 23 g/m2; p = 0.002), was also significantly 
higher in the ATTR group.
Regarding LV dimensions, both telediastolic 
diameter (48 ± 7 mm vs. 53 ± 6 mm; p = 0.004) 
and indexed telediastolic volume (51 ± 18 cm3/m2 
vs. 59 ± 16 cm3/m2; p = 0.004) were significantly 
smaller in amyloidosis group. Telesystolic diam-
eter and indexed telesystolic volume did not show 
statistically significant differences.
Strain data were recorded in only 15 patients. 
Relative apical sparing was significantly higher in 
the CA group (2.2 ± 0.9 vs. 1.03 ± 0.4; p = 0.04). 
Global longitudinal strain showed a clear trend 
towards its reduction in patients with CA (–12 ± 
± 5.5% vs. –19 ± 0.6%; p = 0.078), although dif-
ferences were not statistically significant.
Indexed left atrial volume was very high in 
both groups (55 ± 17 cm3 vs. 51 ± 17 cm3; p = 0.5), 
in the range of severe left atrial dilatation. No sta-
tistically significant differences were found.
Regarding right cavities, both right atrial area 
(27.4 ± 8.4 cm2 vs. 22.2 ± 5.7 cm2; p = 0.04) and 
TAPSE (16 ± 5 mm vs. 20 ± 4 mm; p = 0.004) 
were more affected in the amyloidosis group. 
No significant differences were found in either 
the S’-wave, or the estimation of the pulmonary 
artery systolic pressure, or the right ventricle 
basal diameter.
Finally, regarding diastolic function parameters 
(quotients E/a and E/e’) although a trend towards 
greater involvement was observed in patients with 
CA, no statistically significant differences were 
found. All results are shown in Tables 1 and 2.
Discussion
Cardiac amyloidosis is increasingly relevant 
for several reasons: Non-invasive diagnosis [1] was 
proved to be in higher prevalence of ATTR. In ad-
dition, recent studies with new drugs [13–15] have 
shown therapeutic targets capable of modifying 
the natural history of the disease. This highlights 
the importance of early diagnosis in an entity still 
underdiagnosed [16], among other reasons because 
it presents clinical manifestations that are similar 
to other much more frequent heart diseases [17].
The first test that often leads to CA clinical 
suspicion is the echocardiogram [18]. The most 
common echocardiographic findings in these pa-
tients are interventricular septum thickening and 
Table 1. Basal data.
Total Amyloidosis Non-amyloidosis P
Total number of patients 85 49 36
Male 64 (75.3%) 38 (77.6%) 26 (72.2%) 0.57
Age [years] 80 ± 9 83 ± 9 77 ± 8 0.003*
Arterial hypertension 73 (85.9%) 39 (71.6%) 34 (94.4%) 0.105
Diabetes mellitus 32 (37.6%) 12 (24.5%) 20 (55.6%) 0,03*
Dyslipidemia 52 (61.2%) 26 (53.1%) 26 (72.2%) 0.092*
Glomerular filtration 48 ± 19 48.4 ± 19 48 ± 19 0.88
Ischemic cardiomyopathy 21 (24.7%) 10 (20.4%) 11 (30.6%) 0.28
B-type natriuretic peptide [pg/mL] 10069 ± 12717 10500 ± 13800 9500 ± 11500 0.72
Troponin T [pg/mL] 128 ± 219 180 ± 272 50 ± 27 0.041*
*Sex distribution was similar in both groups. Patients with transthyretin amyloidosis were slightly older. Patients in the control group present-
ed a higher rate of cardiovascular risk factors.
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biauricular dilation. Diastolic dysfunction, with 
restrictive transmitral flow and increased filling 
pressures, is also a frequent finding with reduced 
e’ wave from early stages of the disease. How-
ever, as these alterations are also found in many 
patients with HF, in many cases they do not assist 
in suspecting CA as an etiological diagnosis [19]. 
The speckled myocardial appearance (which has 
the disadvantage of being subjective and therefore 
highly operator dependent) and valve thickenings, 
which are more specific parameters, do not usu-
ally appear until advanced stages of the disease, 
and therefore are not reliable parameters for early 
diagnosis [20]. For all these reasons, it seems in-
creasingly important to find parameters that help to 
select the patients most likely to suffer CA, in order 
to choose the candidates for new diagnostic tests, 
thus, being vital to study the echocardiographic 
characteristics of these patients.
The present study revealed that a greater LV 
wall thickness and smaller LV cavity size (meas-
ured by both diameter and telediastolic volume) 
may help to discriminate CA patients from patients 
with HF and LVH. This data is consistent with 
results in Uzan et al. [6], although in their study 
controls are formed by patients with LVH without 
HF. Also, Boldrini et al. [21], in a recent article 
included the LV wall thickness in a diagnostic 
score of CA in patients with LVH and confirm the 
diagnostic value of the wall thickness and the LV 
mass in these patients (Fig. 3).
The value of different parameters of the right 
ventricle cavities in the echocardiographic di-
agnosis of CA has been previously shown [6]: 
both the parameters of right ventricular systolic 
function (measured as TAPSE, S’ and fractional 
area), and the size of the right atrium and right 
ventricle were significant in this regard, being the 
right ventricular free wall longitudinal strain (RV 
FWLS) the parameter with the greatest power to 
discriminate CA from other pathologies presenting 
hypertrophy. Other studies have already shown 
Table 2. Echocardiographic data.
Total Amyloidosis Other heart failure 
(wall > 12 mm)
P
Interventricular septum [mm] 15 ± 3 16 ± 3 14 ± 3 0.002*
LV posterior wall [mm] 13 ± 3 14 ± 3 11 ± 2 < 0.001*
LVEDD [mm] 50 ± 7 48 ± 7 53 ± 6 0.004*
LVESD [mm] 35 ± 7 35 ± 7 35 ± 6 0.086
LVEDVI [cm3/m2] 55 ± 17 51 ± 18 59 ± 16 0.004*
LVESVI [cm3/m2] 26 ± 11 25 ± 11 27 ± 12 0.49
LV mass [g] 243 ± 68 259 ± 76 224 ± 53 0.026*
Indexed mass [g/m2] 138 ± 38 151 ± 43 123 ± 23 0.002*
LA volume [cm3] 53 ± 17 55 ± 17 51 ± 17 0.5
RA area [cm2] 25 ± 8 27.4 ± 8.4 22.2 ± 5.7 0.04*
RV basal diameter [mm] 40 ± 7 40 ± 9 40 ± 5 0,87
E/A ratio 1.4 ± 0.9 1.7 ± 1 1 ± 0.4 0.062
E/e’ ratio 17.3 ± 7.1 18.1 ± 7.2 16.4 ± 7 0.36
Relative apical sparing 1.7 ± 0.8 2.2 ± 0.9 1.03 ± 0.4 0.04
Global longitudinal strain [%]   –12 ± 5.5 –19 ± 0.7 0.078
TAPSE [mm] 18 ± 5 16 ± 5 20 ± 4 0.004*
S’ wave RV 11.4 ± 4 11.2 ± 4.7 11.7 ± 2.1 0.7
PASP [mmHg] 44 ± 15 44 ± 15 44 ± 14 0.96
LV ejection fraction [%] 54 ± 10 52 ± 10 55 ± 12 0.18
Effusion presence 14 (17%) 9 (23.7%) 5 (14.3%) 0.56
*Interventricular septum thickness, left ventricular posterior wall thickness, left ventricular mass, left ventricular end-diastolic diameter, left 
ventricular end-diastolic indexed volume, tricuspid annular plane systolic excursion, right atrial area and strain relative apical sparing were  
significantly associated with the diagnosis of cardiac amyloidosis. LV — left ventricle; LA — left atrium; RV — right ventricle; RA — right atrium; 
LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; LVEDVI — left ventricular end-diastolic vol-




the systolic involvement of the right ventricle 
measured by TAPSE or the fractional area in 
comparison with controls with LVH, patients with 
amyloidosis without cardiac involvement or healthy 
controls [21–23], as well as the prognostic value of 
such manifestation [22–24]. In the current study, 
in which the control group consisted of patients 
with HF and LVH, the differences in TAPSE and 
right atrial area were equally significant, which 
seems to reinforce the hypothesis that the involve-
ment of the right cavities is an echocardiographic 
finding in favor of the diagnosis of CA. Similar to 
other studies that have studied right ventricular 
function in patients with CA, in the present study 
no difference was found in the pulmonary artery 
systolic pressure estimated through tricuspid 
regurgitation, which reinforces the idea that the 
right dysfunction is due to amyloid infiltration (as 
occurs in other cardiac structures) and not only to 
increased preload.
Regarding those values with no statistical 
significance in the current sample, perhaps the 
most striking is the diastolic dysfunction, which 
in the present study was measured from the E/A 
and E/e’ ratios. In several studies [7, 21] comparing 
patients with CA versus LVH from another origin, 
statistically significant differences were obtained 
for this parameter; the substantial difference lies in 
the fact that the current controls also have HF (un-
like the majority of studies with hypertensive con-
trols or with hypertrophic cardiomyopathy without 
HF) having therefore a greater degree of diastolic 
dysfunction, with a much-increased average filling 
pressure in both groups. Moreover, the fact that 
they are patients admitted for HF provokes that the 
filling pressures of all these patients are even more 
increased. Thus, although the diastolic dysfunction 
is a typical feature in an early-stage of CA, it does not 
appear to be as discriminating as other parameters 
in a cohort of HF and LVH patients.
Figure 3. Echocardiography. The degree of left ventricular hypertrophy, left ventricular reduced size and right atrial 
dilatation increase the suspicion of cardiac amyloidosis.
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Something similar occurs with the LV ejection 
fraction [21] and left atrial volume, which in several 
studies [7, 25] have been shown to discriminate 
CA versus hypertensive patients or patients with 
hypertrophic cardiomyopathy. In one of these 
studies [25], the left atrium in patients with CA 
was in the range of severe dilation (similar to the 
present study) but the control group was composed 
of hypertensive patients, with much less dilated 
atria. In the current study, both groups presented 
means of severe dilation of the left atrium: when 
compared to controls with HF, this parameter is 
not as useful to differentiate patients with cardiac 
amyloidosis. Thus, the results in Liu et al. [7], in 
which the indexed left atrial volume showed high 
specificity to confirm the diagnosis of CA versus 
others with hypertrophic cardiomyopathy or hyper-
tensive heart disease, were not confirmed in the 
present work versus controls with HF.
A parameter that has been widely studied in 
echocardiogram diagnosis, and which diagnostic 
value has been confirmed, is the involvement of the 
global longitudinal strain with preserved apical seg-
ment strain [6, 7, 21, 26, 27]. In the current series, 
despite strain data was only available in a few cases, 
relative apical sparing reached statistical significance, 
in accordance with the literature. Global longitudinal 
strain also showed a tendency to be clearly more 
impaired in patients with amyloidosis (Fig. 4).
Since this is a retrospective observational 
study with a relatively small sample size, specific 
cut off values were not recommended for each one 
of these echocardiograhic parameters. However, 
given the high prevalence of the disease in this 
subgroup of patients (up to 13%) the authors would 
recommend that if severe right atrial dilatation, 
altered right ventricular function or relative apical 
sparing were found in patients with HF and LVH, 
gammagraphy should be mandatory. 
Regarding biomarkers, the diagnostic value 
of the troponin to discriminate patients with CA 
compared to patients with LVH had already been 
highlighted in some studies [28]. The work herein, 
also confirms this point when compared to controls 
with HF.
The present study presents several limita-
tions. First, the fact that only about half of the 
patients with CA have immunofixation prevents 
us from having a diagnosis of certainty of the 
amyloidosis subtype of each patient, therefore, it 
was not possible to specify what type of CA was 
treated in each case. In any case, given that the 
specificity for the diagnosis of ATTR for a grade 2 
or 3 of gammagraphic uptake is 87% and that in the 
follow-up of patients no monoclonal gammopathy 
was subsequently detected, it can be stated that 
the vast majority of the current CA correspond to 
the TTR subtype.




Secondly, the fact that no post-acquisition 
measurements were taken to avoid bias, meant 
that some parameters were not available in many 
patients (affecting mainly to the collection of strain 
values), resulting in a very low statistical power of 
these parameters. Nonetheless, it was considered 
that the fact that all the measurements were made 
by independent echocardiographers, without know-
ing the patient’s diagnosis, adds value to the results 
that were statistically significant.
Regarding the selection of controls, slight dif-
ferences in age can be attributed, but since ATTR 
occurs in many cases at very advanced ages, these 
minimal differences can be considered acceptable. 
In addition, parameters such as NT-proBNP and 
glomerular filtration that have been shown to have 
a high prognostic value [29] were similar. Finally, 
the fact that the controls emerged from the same 
cohort were scanned to rule out CA minimizes any 
selection bias that may exist.
Conclusions
In patients with LVH admitted for cardiac 
decompensation, a series of echocardiographic 
characteristics such as: the degree of LVH, left 
ventricular reduced size, right atrial dilatation, 
altered right ventricular function and strain relative 
apical sparing, increase the suspicion of cardiac 
amyloidosis and are useful for selecting candidates 
for performing Tc-DPD gammagraphy to establish 
diagnosis.
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